Index of reports
> Cases with Infection (13)
Below is the selection of side effect reports (a.k.a. adverse event reports) related to Mesna where reactions include infection. The selected reports were submitted to the FDA during the sample period of about a year.
Possible Mesna side effects in
Reported by a health professional (non-physician/pharmacist) from Croatia (Local Name: Hrvatska) on 2012-06-08
Patient:
Reactions: Infection
Adverse event resulted in: death
Drug(s) suspected as cause:
Etoposide
Dosage: days 4, 5
Indication: Burkitt's Leukaemia
Cytarabine
Dosage: on days 4, 5
Indication: Burkitt's Leukaemia
Methylprednisolone
Indication: Prophylaxis
Mesna
Indication: Burkitt's Leukaemia
Vincristine
Dosage: on day 1
Indication: Burkitt's Leukaemia
Ifosfamide
Dosage: on days 1-5
Indication: Burkitt's Lymphoma
Etoposide
Dosage: days 4, 5
Indication: Burkitt's Lymphoma
Dexamethasone
Dosage: on days 1-5
Indication: Burkitt's Leukaemia
Cytarabine
Indication: Prophylaxis
Rituximab
Indication: Burkitt's Leukaemia
Radiation Therapy NOS
Dosage: 30-36 gy
Indication: Burkitt's Leukaemia
Doxorubicin HCL
Dosage: on days 4, 5
Indication: Burkitt's Leukaemia
Doxorubicin HCL
Dosage: on days 4, 5
Indication: Burkitt's Lymphoma
Cyclophosphamide
Dosage: on days 1-5
Indication: Burkitt's Lymphoma
Vincristine
Dosage: on day 1
Indication: Burkitt's Lymphoma
Methotrexate
Dosage: on day 1 with folinic acid rescue
Indication: Burkitt's Lymphoma
Methotrexate
Indication: Prophylaxis
Mesna
Indication: Burkitt's Lymphoma
Rituximab
Indication: Burkitt's Lymphoma
Cyclophosphamide
Dosage: on days 1-5
Indication: Burkitt's Leukaemia
Ifosfamide
Dosage: on days 1-5
Indication: Burkitt's Leukaemia
Prednisone
Dosage: days 1-5
Indication: Burkitt's Leukaemia
Prednisone
Dosage: days 1-5
Indication: Burkitt's Lymphoma
Leucovorin Calcium
Indication: Burkitt's Leukaemia
Methotrexate
Dosage: on day 1 with folinic acid rescue
Indication: Burkitt's Leukaemia
Cytarabine
Dosage: on days 4, 5
Indication: Burkitt's Lymphoma
Dexamethasone
Dosage: on days 1-5
Indication: Burkitt's Lymphoma
Leucovorin Calcium
Indication: Burkitt's Lymphoma
Radiation Therapy NOS
Dosage: 30-36 gy
Indication: Burkitt's Lymphoma
Other drugs received by patient: Neupogen; Blood Products; Acyclovir; Antibiotics
Possible Mesna side effects in
Reported by a health professional (non-physician/pharmacist) from Croatia (Local Name: Hrvatska) on 2012-06-08
Patient:
Reactions: Infection
Adverse event resulted in: death
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: on days 1-5
Indication: Burkitt's Lymphoma
Vincristine
Dosage: on day 1
Indication: Burkitt's Leukaemia
Ifosfamide
Dosage: on days 1-5
Indication: Burkitt's Lymphoma
Cytarabine
Dosage: on days 4, 5
Indication: Burkitt's Lymphoma
Cytarabine
Indication: Prophylaxis
Prednisone
Dosage: days 1-5
Indication: Burkitt's Lymphoma
Methotrexate
Dosage: on day 1 with folinic acid rescue
Indication: Burkitt's Leukaemia
Methotrexate
Dosage: on day 1 with folinic acid rescue
Indication: Burkitt's Lymphoma
Cytarabine
Dosage: on days 4, 5
Indication: Burkitt's Leukaemia
Mesna
Dosage: on days 1-5
Indication: Burkitt's Leukaemia
Etoposide
Dosage: days 4, 5
Indication: Burkitt's Lymphoma
Methylprednisolone
Indication: Prophylaxis
Mesna
Dosage: on days 1-5
Indication: Burkitt's Lymphoma
Leucovorin Calcium
Indication: Burkitt's Leukaemia
Radiation Therapy NOS
Dosage: 30-36 gy
Indication: Burkitt's Lymphoma
Cyclophosphamide
Dosage: on days 1-5
Indication: Burkitt's Leukaemia
Vincristine
Dosage: on day 1
Indication: Burkitt's Lymphoma
Radiation Therapy NOS
Dosage: 30-36 gy
Indication: Burkitt's Leukaemia
Doxorubicin HCL
Dosage: on days 4, 5
Indication: Burkitt's Leukaemia
Etoposide
Dosage: days 4, 5
Indication: Burkitt's Leukaemia
Prednisone
Dosage: days 1-5
Indication: Burkitt's Leukaemia
Leucovorin Calcium
Indication: Burkitt's Lymphoma
Ifosfamide
Dosage: on days 1-5
Indication: Burkitt's Leukaemia
Dexamethasone
Dosage: on days 1-5
Indication: Burkitt's Lymphoma
Doxorubicin HCL
Dosage: on days 4, 5
Indication: Burkitt's Lymphoma
Dexamethasone
Dosage: on days 1-5
Indication: Burkitt's Leukaemia
Methotrexate
Indication: Prophylaxis
Other drugs received by patient: Neupogen; Acyclovir; Antibiotics; Blood Products
Possible Mesna side effects in
Reported by a health professional (non-physician/pharmacist) from China on 2012-05-11
Patient:
Reactions: Hypersensitivity, Petechiae, Off Label Use, Neurotoxicity, Hepatotoxicity, Granulocytopenia, Bone Marrow Failure, White Blood Cell Count Decreased, Gastrointestinal Toxicity, Anaemia, Nephropathy Toxic, Urinary Tract Infection, Toxicity To Various Agents, Soft Tissue Infection, Sepsis, Platelet Count Decreased, Infection
Drug(s) suspected as cause:
Mesna
Indication: Acute Myeloid Leukaemia
Epirubicin
Indication: non-Hodgkin's Lymphoma
Epirubicin
Indication: Acute Lymphocytic Leukaemia
Methotrexate
Indication: non-Hodgkin's Lymphoma
Cyclophosphamide
Indication: Acute Lymphocytic Leukaemia
Vincristine
Indication: non-Hodgkin's Lymphoma
Methotrexate
Indication: Acute Lymphocytic Leukaemia
Cytarabine
Indication: Acute Lymphocytic Leukaemia
Vindesine
Indication: non-Hodgkin's Lymphoma
Cyclophosphamide
Indication: non-Hodgkin's Lymphoma
Dexamethasone
Indication: Acute Lymphocytic Leukaemia
Vindesine
Indication: Acute Lymphocytic Leukaemia
Vincristine
Indication: Acute Lymphocytic Leukaemia
Dexamethasone
Indication: non-Hodgkin's Lymphoma
Doxorubicin HCL
Indication: non-Hodgkin's Lymphoma
Doxorubicin HCL
Indication: Acute Lymphocytic Leukaemia
Cytarabine
Indication: non-Hodgkin's Lymphoma
Mesna
Indication: non-Hodgkin's Lymphoma
Other drugs received by patient: Leucovorin Calcium
Possible Mesna side effects in
Reported by a health professional (non-physician/pharmacist) from China on 2012-05-10
Patient:
Reactions: Hypersensitivity, Neurotoxicity, Off Label Use, Hepatotoxicity, Granulocytopenia, Bone Marrow Failure, White Blood Cell Count Decreased, Gastrointestinal Toxicity, Nephropathy Toxic, Urinary Tract Infection, Anaemia, Soft Tissue Infection, Acute Lymphocytic Leukaemia, Sepsis, Platelet Count Decreased, Infection
Adverse event resulted in: death
Drug(s) suspected as cause:
Cytarabine
Indication: Acute Lymphocytic Leukaemia
Mesna
Indication: Acute Myeloid Leukaemia
Methotrexate
Indication: non-Hodgkin's Lymphoma
Vincristine
Indication: non-Hodgkin's Lymphoma
Vincristine
Indication: Acute Lymphocytic Leukaemia
Methotrexate
Indication: Acute Lymphocytic Leukaemia
Mesna
Indication: non-Hodgkin's Lymphoma
Vindesine
Indication: Acute Lymphocytic Leukaemia
Vindesine
Indication: non-Hodgkin's Lymphoma
Doxorubicin HCL
Indication: non-Hodgkin's Lymphoma
Cyclophosphamide
Indication: non-Hodgkin's Lymphoma
Cyclophosphamide
Indication: Acute Lymphocytic Leukaemia
Cytarabine
Indication: non-Hodgkin's Lymphoma
Doxorubicin HCL
Indication: Acute Lymphocytic Leukaemia
Dexamethasone TAB
Indication: non-Hodgkin's Lymphoma
Dexamethasone TAB
Indication: Acute Lymphocytic Leukaemia
Other drugs received by patient: Leucovorin Calcium
Possible Mesna side effects in
Reported by a health professional (non-physician/pharmacist) from United States on 2012-03-13
Patient:
Reactions: Stomatitis, Haemoglobin Abnormal, Febrile Neutropenia, Platelet Disorder, Mucosal Inflammation, Diarrhoea, Colitis, Enteritis, Granulocytes Abnormal, Infection
Drug(s) suspected as cause:
Cyclophosphamide
Indication: Neuroblastoma
Topotecan
Dosage: 0.04 mg/kg/day
Indication: Neuroblastoma
Etoposide
Dosage: 6.67 mg/kg/day
Vincristine
Dosage: 0.22 mg/kg/day
Cyclophosphamide
Dosage: 70 mg/kg/day
Doxorubicin HCL
Cyclophosphamide
Dosage: 13.3 mg/kg/day
Cyclophosphamide
Etoposide
Dosage: 6.67 mg/kg/day
Vincristine
Dosage: 0.22 mg/kg/day
Indication: Neuroblastoma
Vincristine
Dosage: 0.22 mg/kg/day
Cyclophosphamide
Dosage: 70 mg/kg/day
Cyclophosphamide
Topotecan
Dosage: 0.04 mg/kg/day
Cisplatin
Dosage: 1.66 mg/kg/day
Mesna
Dosage: 14 mg/kg/day
Cyclophosphamide
Dosage: 70 mg/kg/day
Cyclophosphamide
Topotecan
Dosage: 0.04 mg/kg/day
Cisplatin
Dosage: 1.66 mg/kg/day
Vincristine
Dosage: 0.22 mg/kg/day
Vincristine
Dosage: 0.22 mg/kg/day
Neupogen
Indication: Neutrophil Count
Cyclophosphamide
Dosage: 70 mg/kg/day
Topotecan
Dosage: 0.04 mg/kg/day
Mesna
Dosage: 14 mg/kg/day
Mesna
Dosage: 14 mg/kg/day
Mesna
Dosage: 14 mg/kg/day
Doxorubicin HCL
Dosage: 0.83 mg/kg/day
Indication: Neuroblastoma
Doxorubicin HCL
Topotecan
Dosage: 0.04 mg/kg/day
Cisplatin
Dosage: 1.66 mg/kg/day
Indication: Neuroblastoma
Cisplatin
Dosage: 1.66 mg/kg/day
Etoposide
Dosage: 6.67 mg/kg/day
Cyclophosphamide
Dosage: 70 mg/kg/day
Doxorubicin HCL
Cyclophosphamide
Cisplatin
Cisplatin
Etoposide
Dosage: 6.67 mg/kg/day
Indication: Neuroblastoma
Etoposide
Dosage: 6.67 mg/kg/day
Etoposide
Dosage: 6.67 mg/kg/day
Mesna
Dosage: 14 mg/kg/day
Indication: Neuroblastoma
Mesna
Dosage: 14 mg/kg/day
Vincristine
Dosage: 0.22 mg/kg/day
Cyclophosphamide
Dosage: 70 mg/kg/day
Doxorubicin HCL
Doxorubicin HCL
Topotecan
Dosage: 0.04 mg/kg/day
Possible Mesna side effects in 11 year old male
Reported by a physician from United States on 2012-02-17
Patient: 11 year old male
Reactions: Pyrexia, Infection
Adverse event resulted in: life threatening event, hospitalization
Drug(s) suspected as cause:
Cisplatin
Dosage: 60 mg/m2, unk
Indication: Sarcoma
Start date: 2001-10-02
Ifosfamide
Dosage: 2.8 g/m2, unk
Indication: Sarcoma
Start date: 2001-10-02
Trastuzumab
Dosage: 4 mg/kg, unk
Indication: Sarcoma
Start date: 2001-10-02
Mesna
Dosage: 360 mg/m2, unk
Etoposide
Dosage: unk
Indication: Sarcoma
Start date: 2001-10-02
Methotrexate
Dosage: 12 g/m2, unk
Indication: Sarcoma
Start date: 2001-10-02
Filgrastim
Dosage: 5 mug/kg, unk
Indication: Sarcoma
Start date: 2001-10-02
Leucovorin Calcium
Dosage: 15 mg, unk
Administration route: Oral
Indication: Sarcoma
Start date: 2001-10-02
Doxorubicin HCL
Dosage: 37.5 mg/m2, unk
Indication: Sarcoma
Start date: 2001-10-02
Dexrazoxane Hydrochloride
Dosage: 375 mg/m2, unk
Indication: Sarcoma
Start date: 2001-10-02
Mesna
Dosage: 560 mg/m2, unk
Indication: Sarcoma
Start date: 2001-10-02
Trastuzumab
Dosage: 2 mg/kg, unk
Possible Mesna side effects in
Reported by a individual with unspecified qualification from United States on 2012-02-16
Patient:
Reactions: Confusional State, Psychotic Disorder, Aspartate Aminotransferase Increased, Alanine Aminotransferase Increased, Caecitis, Pericardial Effusion, Infection
Adverse event resulted in: life threatening event, hospitalization
Drug(s) suspected as cause:
Cisplatin
Indication: Osteosarcoma Metastatic
Start date: 2004-09-24
Dexrazoxane
Indication: Osteosarcoma Metastatic
Start date: 2004-09-24
Herceptin
Dosage: loading dose of 4 mg/kg given on day 1
Indication: Osteosarcoma Metastatic
Start date: 2004-09-24
Leucovorin Calcium
Indication: Osteosarcoma Metastatic
Start date: 2004-09-24
Doxorubicin HCL
Indication: Osteosarcoma Metastatic
Start date: 2004-09-24
Methotrexate
Dosage: 12 g/m2
Indication: Osteosarcoma Metastatic
Start date: 2004-09-24
Ifosfamide
Indication: Osteosarcoma Metastatic
Start date: 2004-09-24
Etoposide
Indication: Osteosarcoma Metastatic
Start date: 2004-09-24
Mesna
Indication: Osteosarcoma Metastatic
Start date: 2004-09-24
Possible Mesna side effects in 50 year old male
Reported by a physician from Germany on 2012-01-27
Patient: 50 year old male
Reactions: Fatigue, Diarrhoea, Pancytopenia, Hyperhidrosis, Infection
Drug(s) suspected as cause:
Cyclophosphamide
Dexamethasone
Dosage: 8 mg
Indication: Evidence Based Treatment
Dacarbazine
Indication: Thyroid Cancer
Vincristine
Dacarbazine
Cyclophosphamide
Granisetron
Dosage: 3 mg
Indication: Evidence Based Treatment
Mesna
Dosage: 1200 mg
Cyclophosphamide
Indication: Thyroid Cancer
Vincristine
Indication: Thyroid Cancer
Vincristine
Dacarbazine
Possible Mesna side effects in male
Reported by a physician from United States on 2011-12-23
Patient: male
Reactions: Vomiting, Pain, Tachycardia, Rhinorrhoea, Pyrexia, Irritability, Candida Test Positive, Neutropenic Infection, Escherichia Test Positive, Diarrhoea, Feeling Hot, Tachypnoea, Septic Shock, Cough, Infection
Adverse event resulted in: life threatening event, hospitalization
Drug(s) suspected as cause:
Ifosfamide
Indication: Sarcoma
Start date: 2001-10-02
Cisplatin
Indication: Sarcoma
Start date: 2001-10-02
Methotrexate
Indication: Sarcoma
Start date: 2001-10-02
Doxorubicin HCL
Indication: Sarcoma
Start date: 2001-10-02
Trastuzumab
Dosage: over 90 minutes on day 1, every week for 37 weeks
Indication: Sarcoma
Start date: 2001-10-02
Mesna
Filgrastim
Dosage: then over 15 minutes at hours 8,11,14 post infosamide at 1.8 g/m2 over 4 hours daily for 5 days
Indication: Sarcoma
Start date: 2001-10-02
Leucovorin Calcium
Administration route: Oral
Indication: Sarcoma
Start date: 2001-10-02
Etoposide
Dosage: then over 15 minutes at hours 8,11,14 post infosamide at 1.8 g/m2 over 4 hours daily for 5 days
Indication: Sarcoma
Start date: 2001-10-02
Trastuzumab
Dosage: on day 1(loading dose)
Start date: 2001-10-02
Dexrazoxane Hydrochloride
Indication: Sarcoma
Start date: 2001-10-02
Mesna
Dosage: then over 15 minutes at hours 8,11,14 post infosamide at 1.8 g/m2 over 4 hours daily for 5 days
Indication: Sarcoma
Start date: 2001-10-02
Possible Mesna side effects in 11 year old male
Reported by a consumer/non-health professional from United States on 2011-12-22
Patient: 11 year old male
Reactions: Pyrexia, Infection
Adverse event resulted in: life threatening event, hospitalization
Drug(s) suspected as cause:
Cisplatin
Indication: Sarcoma
Start date: 2001-10-02
Trastuzumab
Indication: Sarcoma
Start date: 2001-10-02
Mesna
Indication: Sarcoma
Start date: 2001-10-02
Doxorubicin HCL
Indication: Sarcoma
Start date: 2001-10-02
Leucovorin Calcium
Administration route: Oral
Indication: Sarcoma
Start date: 2001-10-02
Ifosfamide
Indication: Sarcoma
Start date: 2001-10-02
Etoposide
Indication: Sarcoma
Start date: 2001-10-02
Filgrastim
Indication: Sarcoma
Start date: 2011-10-02
Dexrazoxane Hydrochloride
Indication: Sarcoma
Start date: 2001-10-02
Methotrexate
Indication: Sarcoma
Start date: 2001-10-02
Possible Mesna side effects in 11 year old male
Reported by a physician from United States on 2011-11-29
Patient: 11 year old male
Reactions: Pyrexia, Infection
Adverse event resulted in: life threatening event, hospitalization
Drug(s) suspected as cause:
Ifosfamide
Dosage: 2.8 g/m2, unk
Indication: Sarcoma
Start date: 2001-10-02
Mesna
Dosage: 560 mg/m2, unk
Indication: Sarcoma
Start date: 2001-10-02
Filgrastim
Dosage: 5 mug/kg, unk
Indication: Sarcoma
Start date: 2001-10-02
Cisplatin
Dosage: 60 mg/m2, unk
Indication: Sarcoma
Start date: 2001-10-02
Dexrazoxane Hydrochloride
Dosage: 375 mg/m2, unk
Indication: Sarcoma
Start date: 2001-10-02
Mesna
Dosage: 360 mg/m2, unk
Etoposide
Dosage: unk
Indication: Sarcoma
Start date: 2001-10-02
Trastuzumab
Dosage: 4 mg/kg, unk
Indication: Sarcoma
Start date: 2001-10-02
Doxorubicin HCL
Dosage: 37.5 mg/m2, unk
Indication: Sarcoma
Start date: 2001-10-02
Leucovorin Calcium
Dosage: 15 mg, unk
Administration route: Oral
Indication: Sarcoma
Start date: 2001-10-02
Trastuzumab
Dosage: 2 mg/kg, unk
Methotrexate
Dosage: 12 g/m2, unk
Indication: Sarcoma
Start date: 2001-10-02
Possible Mesna side effects in
Reported by a individual with unspecified qualification from United States on 2011-11-21
Patient:
Reactions: Confusional State, Psychotic Disorder, Aspartate Aminotransferase Increased, Alanine Aminotransferase Increased, Caecitis, Pericardial Effusion, Infection
Adverse event resulted in: life threatening event, hospitalization
Drug(s) suspected as cause:
Ifosfamide
Indication: Osteosarcoma Metastatic
Start date: 2004-09-24
Cisplatin
Indication: Osteosarcoma Metastatic
Start date: 2004-09-24
Leucovorin Calcium
Indication: Osteosarcoma Metastatic
Start date: 2004-09-24
Methotrexate
Indication: Osteosarcoma Metastatic
Start date: 2004-09-24
Herceptin
Dosage: loading dose of 4 mg/kg given on day 1
Indication: Osteosarcoma Metastatic
Start date: 2004-09-24
Doxorubicin HCL
Indication: Osteosarcoma Metastatic
Start date: 2004-09-24
Dexrazoxane Hydrochloride
Indication: Osteosarcoma Metastatic
Start date: 2004-09-24
Mesna
Indication: Osteosarcoma Metastatic
Start date: 2004-09-24
Etoposide
Indication: Osteosarcoma Metastatic
Start date: 2004-09-24
Possible Mesna side effects in
Reported by a health professional (non-physician/pharmacist) from France on 2011-10-31
Patient:
Reactions: Toxicity To Various Agents, Infection
Adverse event resulted in: death
Drug(s) suspected as cause:
Doxorubicin HCL
Cyclophosphamide
Mesna
Eldisine
Indication: Lymphoma
Eldisine
Eldisine
Bleomycin Sulfate
Methotrexate
Indication: Lymphoma
Bleomycin Sulfate
Doxorubicin HCL
Indication: Lymphoma
Eldisine
Bleomycin Sulfate
Indication: Lymphoma
Cyclophosphamide
Mesna
Prednisone
Administration route: Oral
Indication: Lymphoma
Cyclophosphamide
Indication: Lymphoma
Mesna
Indication: Lymphoma
Mesna
Bleomycin Sulfate
Doxorubicin HCL
Doxorubicin HCL
Cyclophosphamide
Other drugs received by patient: Neupogen
|